Details
Stereochemistry | ACHIRAL |
Molecular Formula | C30H50 |
Molecular Weight | 410.718 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 4 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C
InChI
InChIKey=YYGNTYWPHWGJRM-AAJYLUCBSA-N
InChI=1S/C30H50/c1-25(2)15-11-19-29(7)23-13-21-27(5)17-9-10-18-28(6)22-14-24-30(8)20-12-16-26(3)4/h15-18,23-24H,9-14,19-22H2,1-8H3/b27-17+,28-18+,29-23+,30-24+
Squalene is a naturally occurring polyprenyl compound primarily known
for its key role as an intermediate in cholesterol synthesis. It received its name because of its occurrence in shark liver oil (Squalus spp.), which contains large quantities and is considered the richest source of squalene. However, it is widely distributed in nature, with reasonable
amounts found in olive oil, palm oil, wheat-germ oil, amaranth oil, and rice bran oil. The primary
therapeutic use of squalene currently is as an
adjunctive therapy in a variety of cancers. Although
epidemiological, experimental and
animal evidence suggests anti-cancer properties,
to date no human trials have been conducted
to verify the role this nutrient might
have in cancer therapy regimens.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map00100 Sources: http://www.genome.jp/dbget-bin/www_bget?cpd:C00751 |
|||
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20161970 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
27 g 1 times / day multiple, oral Highest studied dose Dose: 27 g, 1 times / day Route: oral Route: multiple Dose: 27 g, 1 times / day Sources: Page: p.503 |
healthy, ADULT n = 20 Health Status: healthy Age Group: ADULT Sex: F Food Status: FED Population Size: 20 Sources: Page: p.503 |
Other AEs: Loose stools... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Loose stools | 55% | 27 g 1 times / day multiple, oral Highest studied dose Dose: 27 g, 1 times / day Route: oral Route: multiple Dose: 27 g, 1 times / day Sources: Page: p.503 |
healthy, ADULT n = 20 Health Status: healthy Age Group: ADULT Sex: F Food Status: FED Population Size: 20 Sources: Page: p.503 |
PubMed
Title | Date | PubMed |
---|---|---|
Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. | 2003 Nov 1 |
|
Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. | 2004 Sep |
|
Two new sesquiterpenoids and anti-HIV principles from the root bark of Zanthoxylum ailanthoides. | 2005 Nov 1 |
|
Benzopyrans, biphenyls and xanthones from the root of Garcinia linii and their activity against Mycobacterium tuberculosis. | 2006 Apr |
|
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. | 2008 Apr 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17313043
The efficacy of diets with different contents of squalene (100, 200, 400, 600 mg per day) was compared. It was shown that antiatherosclerotic diet with inclusion 600 mg squalene has promoted the most positive changes of immune status. The consumption of 200-400 mg of squalene per day produced the more significant antioxidant effect.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14602142
Squalene (12.5-25 uM) treatment significantly protected the CFUs (human bone marrow (BM) derived colony-forming unit) from cisplatin-induced toxicity
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C860
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
||
|
LOINC |
79326-5
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
||
|
DSLD |
1853 (Number of products:19)
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m10166
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000091876
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
638072
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
D013185
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
C77219
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
7QWM220FJH
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
10014
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
ALTERNATIVE | |||
|
SUB25541
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
111-02-4
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
SQUALENE
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
8242
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
15440
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
253201
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
7QWM220FJH
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
DTXSID0026044
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
203-826-1
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY | |||
|
DB11460
Created by
admin on Sat Dec 16 20:10:29 GMT 2023 , Edited by admin on Sat Dec 16 20:10:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY